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Two novel triple negative breast cancer cell lines, NIPBC-1 and NIPBC-2 were successfully established from primary
tumors of two young breast cancer patients aged 39 and 38 years respectively, diagnosed as infiltrating duct carcinoma
of breast. Characterization of these cell lines showed luminal origin with expression of epithelial specific antigen and
cytokeratin 18 and presence of microfilaments and secretary vesicles, microvilli, tight junctions and desmosomes on
ultra-structural analysis. Both the cell lines showed anchorage independent growth and invasion of matrigel coated
membranes. Karyotype analysis showed aneuploidy, deletions and multiple rearrangements in chromosomes 7, 9, X
and 11 and isochromosomes 17q in both the cell lines. P53 mutational analysis revealed no mutation in the coding
region in both the cell lines; however NIPBC-2 cell line showed presence of heterozygous C/G polymorphism,
g.417 C > G (NM_000546.5) resulting in Arg/Pro allele at codon 72 of exon 4. Screening for mutations in
BRCA1&2 genes revealed presence of three heterozygous polymorphisms in exon 11 of BRCA1 and 2 polymorphisms
in exons 11, and14 of BRCA2 gene in both the cell lines. Both the cell lines showed presence of CD 44+/24-breast
cancer stem cells and capability of producing mammosphere on culture. The two triple negative breast cancer
cell lines established from early onset breast tumors can serve as novel invitro models to study mechanisms
underlying breast tumorigenesis in younger age group patients and also identification of new therapeutic modalities
targeting cancer stem cells.
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Breast cancer is the leading cause of cancer deaths
among women, accounting for 23% of the total cancer
incidence and 14% cancer deaths globally [1]. In India
breast cancer has emerged as most common cancer in
women, which was earlier reported as second most com-
mon cancer after cancer of cervix [2], the age adjusted
annual incidence rate (AAR) ranging from 25-33 cases
per 100,000 women in urban population and 7.2 in rural
areas [2]. Around 100,000 women are diagnosed with* Correspondence: sunita_saxena@yahoo.com
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article, unless otherwise stated.carcinoma breast every year in India, of which around
50,000 women die with the disease every year with a
predicted rise to 131 000 cases by 2020, and increased
concentration in urban areas [3]. The incidence of breast
cancer in Indian population (1/35) is not as high as in
the western countries (1/8) however, the incidence of
early onset of breast cancer cases (<40 years) does not
show significant variation in women worldwide (12-33
per 100,000 women); suggesting that a greater propor-
tion of all breast cancers is mainly due to early onset of
disease in Indian population [1,4]. The average age of
onset of breast cancer in Indian patients ranges between
40-50 years compared to 60-70 in western countries.
Breast cancer diagnosed at young age is well recognized
as clinically different than breast cancers diagnosed at
older ages [5]. Younger patients more frequently exhibittral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Pandrangi et al. Cancer Cell International 2014, 14:14 Page 2 of 20
http://www.cancerci.com/content/14/1/14aggressive features such as large tumor size, high histological
grade, positive lymph nodes, absence of steroid receptors
and high S-phase fraction, and young age itself has been
shown to be an independent predictor of adverse prognosis
[6-9]. Majority of Indian breast cancer patients are young
(<40 yrs), married and having children at younger age with
history of breast feeding their children for long duration.
The development of breast cancer in these young women is
an enigma. There is not much information available re-
garding the molecular mechanism and etiological fac-
tors responsible for the breast cancer at young age;
hence there is a need for establishing an experimental
tool to investigate it.
Cell lines provide an important experimental tool in
cancer research with major benefit of infinite supply of a
relatively homogeneous cell population that is capable of
self-replication which can be widely distributed to facili-
tate comparative studies. Cell cultures established dir-
ectly from human tumors serve as unique models for
studying and manipulating the potentially relevant mo-
lecular and cellular processes underlying malignant dis-
ease and identification of novel biological therapeutic
targets. Majority of breast cancer derived cell lines are
from secondary tumours and pleural effusions of pa-
tients with advanced stage breast cancers [10-18]. Few
breast cancer cell lines have been successfully estab-
lished from primary tumours [19-24]. Among the avail-
able breast cancer cell lines, majority of cell lines are
established from cancers from older age group patients
(> 55 yrs), only a small proportion of breast cancer cell
lines are established from patients <40 years of age. To
establish a tool to elucidate the molecular pathogenesis
of breast cancer in young Indian women who usually ex-
hibit major reproductive protective factors for breast
cancer, we have established two breast cancer cell lines,
NIPBC-1 and NIPBC-2 from primary tumours of two
young breast cancer patients (<40 yrs). These two cell
lines are triple negative which is most common pheno-
type seen in breast tumours in young women.
Materials and methods
Establishment and purification of primary cultures
Primary cultures were established from tumour tissue
obtained from breast cancer patients, who underwent
modified radical mastectomy (MRM) or tru-cut biopsies
at Safdarjung hospital, New Delhi, India. A part of bi-
opsy was used for frozen section/paraffin embedding to
confirm the diagnosis and presence of tumor cells in it.
The tumour tissue was collected in DMEM supple-
mented with antibiotics (penicillin 100 U/ml, strepto-
mycin 100 μg/ml). The tissue was then washed with PBS
supplemented with antibiotics, minced into 1-2 cu.mm
pieces removing blood, fat and fibro connective tissue used
for enzymatic disaggregation. Enzymatic disaggregationwas carried out by incubating the small tissue pieces with
2.5% crude trypsin for 30 minutes at 37°C and with colla-
genase (0.15%) overnight. Cells released after enzymatic
treatment were tested for cell viability using trypan blue
and then seeded on to tissue culture flasks and maintained
in DMEM medium supplemented with 10-20% FBS,
Glutamine 2 mM, and growth factors such as epider-
mal growth factor (5-15 ng/ml) insulin 100 U/ml. The
cells were then maintained in DMEM medium supple-
mented with 10% FBS and growth factors at 37°C in a
humidified atmosphere of 5% CO2 and 95% air. Growth
factors were gradually withdrawn from the primary cul-
tures after their purification and were presently being
maintained in DMEM medium supplemented with 10%
FBS and 2 mM Glutamine. Once the cultures were
80- 90% confluent, the cells were trypsinised with
0.05% trypsin and split in a ratio of 1:3 in fresh
DMEM medium. Also, the cells were sampled and frozen
periodically at various passages. Both NIPBC-1 and NIPBC-
2 were completely purified and passaged for 85 and 66
times respectively and characterised thoroughly.
Characterisation of established cell lines
Phenotypic characterization
(i) Immunoflourescence
For immonocytochemical analysis cells were grown
on cover slips, fixed with methanol-acetone/ 4%
paraformaldehyde and incubated with monoclonal
antibodies for Estrogen receptor (ER), Progesterone
receptor (PR), HER2/neu, Pan-Cytokeratin,
Cytokeratins 5/6 and 18, vimentin, epithelial
membrane antigen (EMA), Mucin 1 and P53.
These cover slips were further incubated with
secondary antibody conjugated with FITC
(DAKO) and counterstained with propidium iodide
(Sigma). Fluorescence was detected using fluorescence
microscope.(ii) Flowcytometry
Cells were trypsinised to form a single cell
suspension, counted and washed with ice cold
staining buffer (1× PBS with 3% FBS and 0.05%
sodium azide). Approximately, 1× 106 cells were
resuspended in 500 μl of ice cold staining buffer
and 3 μl of FITC conjugated Ki67 or primary
antibodies of p53 were added and incubated for
30 minutes at 4°C in dark. The cells were then
washed and incubated subsequently with FITC
conjugated secondary antibodies (for P53 and P21).
After incubation the cells were washed twice by
centrifugation at 400 g for 5 minutes and
resuspended in 1 ml of ice cold staining buffer and
kept on ice until analysis. Appropriate isotype
controls have been used.
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For ultrastructure studies, cultured cells were double fixed
with 1.2% glutaraldehyde in 0.01 M phosphate-buffered sa-
line (pH 7.5) and with 2.0% glutaraldehyde for l hr at 4°C.
Post-fixation was performed with 1% OsO4. The sample
was embedded in epoxy resin. The ultra- thin sections
were cut (400-500 μ), stained by lead citrate and uranyl
acetate and studied under transmission microscope [25].
Softagar assay
The ability of anchorage-independent growth of the puri-
fied cancer epithelial cells was determined by growing the
cells on semisolid agar at 25th and at 40th passages. A
single-cell suspension containing 105 cells/35-mm petri
dish was dispersed in a solution containing 0.3% bacto-
agar in epithelial culture medium described above. This
was then layered over a 0.6% bacto-agar solution in
DMEM/F12 supplemented with 10% FBS and fed bi-
weekly with epithelial cell culture medium. Formation
of colonies was determined by inverted microscopy for
2-3 weeks post-seeding [26].
Karyotyping
Karyotyping of both NIPBC-1 and NIPBC-2 cell lines
has been done at both early passages (P20 and P15 re-
spectively) and late passages (P65 and P52 respectively)
to facilitate cytogenetic examination and comparison of
the karyotypes between early and late passages. Briefly,(c)
(a) 
Figure 1 Establishment of NIPBC-1 cell line showing stages of (a) Initi
NIPBC-1 cell line.cells were plated at approximately 1-2 × 106/75 cm2
flask. After 48 hrs cells were exposed to 0.1 μg of colchi-
cine (Sigma) at 37°C, for 3 hrs. The cells were then har-
vested by trypsinization, incubated for 20 minutes at
room temperature with a hypotonic solution (75 mM
KCL) and fixed with methanol: acetic acid (3:1). Slides
were prepared and stained with GIEMSA. G banding
was done to analyse chromosomal aberrations [27].
Population doubling time
The doubling time of both NIPBC-1 and NIPBC-2 cell
lines at passage 35 and 32 respectively, was determined
by counting the cell number at regular intervals. On day
0, 1 × 105 viable cells were seeded in triplicate in each of
six well plates (corning, USA) in DMEMF12 culture
medium. Cells were counted in triplicate with a Neu-
bauer chamber at exactly 24 hr intervals for a series of
10 days after staining with trypan blue dye. The growth
curve was plotted and the doubling time was calculated
from regression equation of the curve [28-31].
DNA finger printing/STR profiling
STR profiling of NIPBC-1 and NIPBC-2 cell lines was done
using StemElite ID System kit (Promega) as per the manu-
facturer’s instructions. This method allows identification of
unique detection of short tandem repeats, seven human
STR loci, Amelogenin (for gender identification) and one
mouse locus, which include TPOX, vWA, Amelogenin,(b) 
ation (b) purification and (c) completely purified confluent
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These loci collectively provide a genetic profile with a ran-
dom match probability of 1 in 2.92 × 109 (while simultan-
eously providing detection of a 1% fraction of mouse
contaminant in a human cell line). The eleven loci are
amplified simultaneously in a single tube and analyzed by
capillary electrophoresis on 3130xl genetic analyzer (Ap-
plied Biosystems, Foster City, CA, USA).
Invasion assay
To assess the invasive capacity of NIPBC-1 and NIPBC-
2 cells, we utilized Corning invasion chambers and
coated them with matrigel; MDA-MB-231 cells were
used as positive control. Cells were trypsinised and
washed twice with PBS before they are transferred to the
invasion chamber. Prior to use, chambers were rehy-
drated with DMEM for 2 hours at 37°C then plated with
5 × 104 cells per well. After 12 hours of incubation, inva-
sion chambers were fixed in 4% paraformaldehyde for
15 minutes, stained with hematoxylin, and washed in
PBS. Cancer cells that invaded through the matrigel-
coated filter on the lower membrane were manually
counted under a microscope. Four randomly chosen
fields were counted for each well. The experiment was
performed in triplicates.
Mycoplasma detection
The mycoplasma DNA was detected by the PCR kit
Venor GeM (Minerva Biolabs) as per the manufacturer’s
instructions. This kit is specific for a spectrum of(c)
(a) (
Figure 2 Establishment of NIPBC-2 cell line showing stages of (a) Initi
NIPBC-2 cell line growing in layers.contaminants of cell lines and their biological derivatives
belonging to Mycoplasma acholeplasma and ureaplasma
species. The primer set is specific to the highly conserved
16S rRNA coding region in the mycoplasma genome. De-
tection requires as little as 1–5 fg of mycoplasma DNA
corresponding to 2–5 mycoplasma per sample volume.
The resulting PCR products were separated by electro-
phoresis in 1.5% agarose gel, stained with ethidium brom-
ide, visualized under UV light and documented by
photography.BRCA1 & 2 mutational screening
The complete coding regions and exon-intron boundar-
ies for BRCA1 gene were screened for DNA sequence
variants by automated sequencing on 3130 × l genetic
analyzer (Applied Biosystems, Foster City, CA, USA).
DNA was isolated from both the cell lines. 100 ng of
genomic DNA was used for PCR amplification with
BRCA1&2 specific primers as mentioned in Saxena et.al.
(2006) [32].Mutational analysis of TP53
Genomic DNA was isolated from NIPBC-1 and NIPBC-2
cell lines using Gene aid DNA isolation kit as per the
manufacturer’s instructions. Polymerase chain reaction
(PCR) amplified products encompassing exons 2- 3, 4,
5-6, 7, 8, 9, 10 and 11 of the TP53 gene were analyzed for
mutations by automated sequencing using 3130xl genetic
analyzer (Applied Biosystems, Foster City, CA, USA).b)
ation (b) purification and (c) completely purified confluent
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(i) Aldefluor assay and flow cytometryFigu
(c) CyAldefluor assay was performed as per the
manufacturer’s instructions (StemCell
Technologies, Vancouver, BC, Canada) in NIPBC-1,
NIPBC-2 and MCF7 breast cancer cell lines. Briefly,
single cells obtained from cell cultures were incu-
bated in Aldefluor assay buffer containing an ALDH
substrate, bodipy-aminoacetaldehyde (BAAA,
1 μmol/L per 1,000,000 cells), for 30 min at 37°C.
A fraction of cells from each sample, incubated
under identical condition in the presence of diethyla-
minobenzaldehyde (DEAB) was taken as negative
control [33]. Flow cytometry was conducted using
FACS ARIA II SORP (Special order research product)
(Becton Dickinson). ALDEFLUOR florescence was ex-
cited at 488 nm and florescence emission was detected
using a standard FITC 530/30 band pass filter. The
sorting gates were established using the negative con-
trol [34,35].(ii) Identification of CD44+/CD24- breast cancer stem
cells by flow cytometry(g) (h) 
(d) (e)
(a) (b)
re 3 Expression of biological markers in the established breast cancer cell
tokeratin 5/6, (d) Estrogen receptor, (e) Progesterone receptor, (f) HER2/neu (g)Al- Hajj and collegues have demonstrated that
expression of stem-cell markers CD44+/CD24−/low
in mammary tumors has prognostic significance
[36]. Breast cancer cell line MCF7 was taken as a
positive control. To sort tumor cells with CD44
and CD24 markers both NIPBC-1 and NIPBC-2
cell lines were trypsinized to make single cell
suspensions. Approximately, 1 × 107 cells suspended
in 1 ml of staining buffer were stained with fluoro-
chrome conjugated monoclonal antibodies against
human CD44 (PE) and CD24 (FITC) both individually
and in combinations. The isotype controls were also
added to the cell suspensions as per the manufac-
turer’s instructions and were incubated in the dark
for 45 min. Unbound antibody was washed off and
cells were analyzed for the presence of CD44+/CD24-
cell population, no longer than 2 hr post staining on
BD FACS ARIA. The sorting gates were established
using the isotype matched controls [36].
This study had been approved by institutional
ethics committee of Safdarjung Hospital, New Delhi
and consent has been obtained from each patient
for participating in this study.(f) 
(c) 
line NIPBC-1. (a) Epithelial membrane antigen, (b) Cytokeratin 18,
P53 and (h) Vimentin.
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Establishment of primary cultures
We have initiated 31 primary cultures using 44 biopsies
obtained from patients diagnosed with carcinoma of
breast. Out of these primary cultures, 2 cell lines could
be successfully purified and propagated for more than
60 passages. Among the two cell lines established,
NIPBC-1 was derived from a breast cancer patient aged
39 years and NIPBC-2 from a 38 year old patient. The
breast tumor in both the cases has been diagnosed as In-
filtrating breast cancer NOS type, grade IIb and grade III
respectively. The two cell lines were established by enzym-
atic disaggregation followed by differential trypsinization.
NIPBC-1 was initiated after enzymatic disaggregation of
tumor tissue with trypsin. Cells were seeded onto the sur-
face of a flask and cells which adhered to the surface by
day 1, reached confluency by day 10; the cells were then
subjected to differential trypsinization, until a pure epithe-
lial cell population is remained in the flask. NIPBC-1 cells
are spindle shaped cells which grow sparse, do not grow
in layers and adhere strongly to the surface (Figure 1). The
second cell line NIPBC-2 was initiated by enzymatic dis-
aggregation with both trypsin and collagenase; the cells
adhered to the surface after day 3, and formed cell
aggregates consisting of epithelioid cells. These cells(a) (b)
(d) (e)
(g)
Figure 4 Expression of biological markers in the established breast ca
(b) Cytokeratin 18, (c) Cytokeratin 5/6, (d) Estrogen receptor, (e) Progesteroproliferated and occupied the whole surface by day 8.
They formed distinct large epithelial colonies surrounded
by fibroblasts, which were further enriched by selective
scraping of the fibroblasts. NIPBC-2 cells are cuboidal
cells which form multilayers. They are fast growing, and
easily get detached upon trypsinization. NIPBC-1 and
NIPBC-2 cell lines were so far passaged for 85 and 66
times respectively in our laboratory (Figure 2).
Expression of epithelial and biological markers
Expression of epithelial markers EMA, Cytokeratin-18,
5/6, mesenchymal marker vimentin, Estrogen receptor
and P53 was studied in the established cultures by immu-
noflorescence (Figures 3 and 4) and immunocytochem-
istry (data not shown) to determine their histogenesis.
Both NIPBC-1 and NIPBC-2 cells showed immunonega-
tivity for cytokeratin 5/6 and are found to be non-
basal. Both the cell lines were found to be triple nega-
tive (ER -ve, PR -ve and HER2/neu –ve). While the
NIPBC-1 cell line showed over expression of cytoplas-
mic Muc1, but was found p53 negative. NIPBC-2 cell
line did not show expression of Muc1 but showed a
strong nuclear positivity for p53.
Further we have analyzed expression of cell cycle
markers viz., Ki67, p53 and p21 proteins by flow(c)
(f)
ncer cell line NIPBC-2. (a) Epithelial membrane antigen,
ne receptor, (f) HER2/neu and (g) P53.
(a) (b)
Figure 5 Expression of cell cycle markers by FACS in NIPBC-1 cell line. (a) P53 (0.26%) and (b) P21 (11.13%).
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NIPBC-1 and NIPBC-2 (Additional file 1: Figure S1),
whereas p53 expression was found only in NIPBC-2
confirming the immunofluorescence finding. Both the
cell lines demonstrated only negligible amounts of p21
(Figures 5 and 6).Electron microscopic analysis
The epithelial lineage of both NIPBC-1 and NIPBC-2
cells was further confirmed by ultrastructure study of
the cells by transmission electron microscopy. The cells
from both the cell lines showed presence of hyperchro-
matic vesicular nucleus with 2 or 3 nucleoli. The cyto-
plasm showed presence of ribosomes, bundles of
microfilaments and secretary vesicles. The cells were
polygonal and attached to each other with tight(a)
Figure 6 Expression of cell cycle markers by FACS in NIPBC-2 cell linejunctions and desmosomes. Few microvilli were also
present at the cell surface (Figure 7).
Anchorage independent growth
NIPBC-1 and NIPBC-2 when plated as single suspension
on 0.3% agar, formed large colonies (40-100) after
2 weeks, MCF7 cell lines were used as positive control
for this experiment which also formed large colonies on
agar (Figure 8).Population doubling time
Population doubling time of cell lines NIPBC-1 and
NIPBC-2 cell lines were determined as described in ma-
terials and methods. The doubling time of NIPBC-1 cell
line was found to be 33.25 hrs, while that of NIPBC-2
was 31.56 hrs (Figure 9).(b)
. (a) P53 (91.80%) (b) P21 (4.25%).
Figure 7 Electron micrographs of the established cell lines.
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Karyotype analysis of NIPBC-1 and NIPBC-2 cells has
shown that both the cell lines possess aneuploidy. Chro-
mosomes 7, 9, X and 11 showed deletions in various re-
gions in both the cell lines. Cytogenetic analysis has
shown multiple rearrangements. NIPBC-1 was near
tetraploid with a modal number of 58 to 62 chromo-
somes, most of the chromosomes exhibited several trans-
locations and marker chromosomes; rearrangements like t
(14:15) (q12:q12) and i(17q) were found commonly in
these cells; Isochromosomes 17q was the most common
aberration identified in NIPBC-1 (Figure 8). NIPBC-2 cell
line was also found to be aneuploid with nearly tetraploidto pentaploid complement and the chromosomal numbers
ranged from 107 to110 (Figures 10 and 11). No significant
karyotype changes were found in the karyotypic analysis
among the early and late passages of both the cell lines;
indicating that both NIPBC-1 and NIPBC-2 are stable cell
lines.
DNA finger print/STR analysis
STR profiling of standard STR markers [37] was done
for both NIPBC-1 and NIPBC-2 cell lines established
distinct profiles of both the cell lines. (Additional file 2:
Table S1) Both the cell lines did not show any peak for







Figure 8 Representative pictures of colonies formed in anchorage independent growth by (a) NIPBC-1 and (b) NIPBC-2 cell lines at
(i) day 1, (ii) day 7 and (iii) day 14.
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shows that both the cell lines are from female origin with
XX chromosomes. Further, this analysis established the
fact that there is no cross contamination among the two
cell lines.Invasion assay
To examine the invasion capacity of the two cell lines
established in the present study, we have carried out in-
vasion assay on matrigel coated membrane inserts. We
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Figure 9 Population doubling time: cells were plated in 6-well
plates at a plating density of 1 × 105 cm2 in DMEM growth
medium, supplemented with 10% FBS. Growth medium was
renewed every 3 days. Cell counts were performed on the days
indicated. Each point represents the mean of three different
determinations made in triplicate. The population doubling times
of the established cell lines (a) NIPBC-1 and (b) NIPBC-2 were
calculated to be 33.25 hrs and 31.56 hrs respectively.
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Breast cancer cell line MDA-MB231 was taken as posi-
tive control. The number of cells invading the matrigel
matrix are counted in atleast 4 randomly choosen fields
per well. The numbers of MDA-MB231, NIPBC-1 and
NIPBC-2 cells that invaded through the basement mem-
brane were 527 ± 45.9020, 409.3 ± 32.3161, 290.6 ± 44.2417
respectively (Figure 12a-c). The number of NIPBC-1 cells
that invaded through the basement membrane was signifi-
cantly higher than that of NIPBC-2 cell line (p = 0.0407)
(Figure 12d).
Test for mycoplasma contamination
Various passages of both NIPBC-1 and NIPBC-2 cell
lines were tested for the presence of mycoplasma by aPCR based method using “Venor GeM Mycoplasma de-
tection kit”. Both the cell lines have been found to be
free of mycoplasma contamination (Figure 13).
BRCA gene status
BRCA1 gene status in the two established cell lines was
checked by automated sequencing, no mutation was de-
tected in the coding regions. Further, we found four het-
erozygous polymorphisms in exon 11 of BRCA1 and two
polymorphisms in exons 11, and 14 of BRCA2 gene in
these cell lines (Figure 14) (Additional file 3: Table S2).
TP53 mutational analysis
No mutation was found in the coding regions of both
NIPBC-1 and NIPBC-2 cell lines.
NIPBC-2 cell line has heterozygous C/G, g.417 C>G
(NM_000546.5), at codon72of exon 4, resulting in p.
P72R (Pro/Arg allele); While, NIPBC-1 has homozygous
Pro/Pro allele (no change), at codon 72 (Figure 15)
(Additional file 4: Table S3).
Expression of breast cancer stem cells by flow cytometry
To obtain breast CSCs, we have stained and sorted both
NIPBC-1 and NIPBC-2 cell lines using antibodies
against CD44 and CD24 cell surface markers taking
MCF7 breast cancer cell line as positive control. Al-
though we could detect 0.2% and 0.1% of CD44+/CD24-
breast cancer stem cells in NIPBC-1 and NIPBC-2 cell
lines respectively (Figure 16); expression of ALDH-
positive BCSCs was not found (data not shown).
Discussion
We have established two triple negative breast cancer
cell lines NIPBC-1 and NIPBC-2 from primary tumors
of two young breast cancer patients (39 and 38 yrs old)
both showing nonbasal origin. In India premenopausal
patients constitute about 50% of all patients. Early-onset
breast cancer may, in part, be biologically different from
breast cancer patients in older patients [38]. Family his-
tory contributes to only 20% of the early onset cases
whereas factors responsible for the rest of the breast
cancer cases in young women are not known [39]. Dif-
ference in clinical behavior and molecular profile of early
onset breast cancer suggest the need for understanding
the risk factors and molecular mechanisms involved in
development of breast cancer in young women. There
are few breast cancer cell lines available (<20%) from pa-
tients <40 years of age. The two cell lines established in
the present study NIPBC-1 and NIPBC-2 were derived
from breast cancer patients with the age 39 years and
38 years respectively, and represent breast cancers that
occur at early age; hence may serve as in vitro models to
study the early onset breast cancers in Indian women.




Figure 10 Representative metaphases (a, b) of NIPBC-1 cells, at passages 20 and 65, with trypsin-giemsa banding. Karyotypes (c, d) of
the above metaphases showing near tetraploidy with a modal number of 58 to 62 chromosomes.





Figure 11 Representative metaphases (a, b) of NIPBC-2 cells, at passages 15 and 52, with trypsin-giemsa banding. Karyotypes (c, d) of
the above metaphases showing near tetraploidy with a modal number of 58 to 62 chromosomes.
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which is comparable to other studies in breast cancer
where also low success rate had been reported [40]. The
epithelial origin of both the cell lines, NIPBC-1 and
NIPBC-2 has been confirmed by electron microscopic
examination and immunofluorescence. Both NIPBC-1and NIPBC-2 cells are negative for cytokeratin 5/6 and
positive for EMA, demonstrating their non-basal epithe-
lial nature. NIPBC-1 cells showed over expression of
MUC1 cells, suggesting their transformed nature [41,42],
further it has shown punctate vimentin positivity sug-




































Figure 12 Invasion assay of NIPBC-1 and NIPBC-2 cell lines. Representative pictures of (a) MDA MB 231 (positive control), (b) NIPBC-1 and
(c) NIPBC-2 cells invaded through Matrigel. (d) Cell number quantification of invasion.
Pandrangi et al. Cancer Cell International 2014, 14:14 Page 13 of 20
http://www.cancerci.com/content/14/1/14corroborating with their spindle shape. Vimentin has
been previously linked to the metaplastic potential of
cancer cells as its increased expression has been de-
monstrated to be a marker of epithelial mesenchymal -
transition (EMT). Also Willipinski-Stapelfeldt et al., [43]
stained more than 2500 primary breast tumors and dem-
onstrated that approximately 35% of hormone receptor
negative tumors expressed vimentin but only 7% of hor-
mone receptor positive tumors expressed vimentin. Also
Connie L. Sommers et al., [44] reported that vimentin was
expressed by more than one-half of the hormone-independent breast carcinoma cell lines tested but not by
the hormone-dependent cell lines. Moreover it is a well
established fact that most eukaryotic cells start expressing
vimentin when brought into tissue culture [45,46].
Vimentin which was originally identified as an inter-
mediate filament protein present only as an intracellular
component has been detected recently on the surface of
cancer cells but not on healthy cells in a punctate distri-
bution pattern. Nicole F. Steinmetz et al., [47,48] have
demonstrated that surface vimentin can be used as a


































Figure 13 Test for mycoplasma contamination in NIPBC-1 and
NIPBC-2 cell lines.
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vimentin with the CD44 and CD133 stem- or progenitor
cell marker proteins and demonstrated that Cowpea mo-
saic virus (CPMV) nanoparticles can bind to the surface
domains of vimentin thereby facilitating drug targeting
in prostate cancer. NIPBC-1 cell line which expresses
punctate surface vimentin can be used as a model for
creating nanoparticle- or antibody- cancer therapeutic
agents capable of targeting vimentin in combination
with other surface markers to prevent cancer metastasis
as well as kill cancer stem cells. Also it can be used as a
model to detect highly metastatic cancer cells.
The ultra structural features confirming epithelial origin
of both the cell lines include presence of bundles of mi-
crofilaments, secretary vesicles, tight junctions, desmo-
somes, and granular cytoplasm with numerous ribosomes.
Both NIPBC-1 and NIPBC-2 cell lines are negative for es-
trogen receptor (ER), progesterone receptor (PR) and
HER2/neu, and hence represent triple negative breast can-
cers (TNBC), which are considered to be aggressive tu-
mors having higher histological grade, worse prognosis
and occur mostly in younger women [49-51]. Most of the
triple negative tumors are of basal type [51], however, the
two cell lines we have established are triple negative but
are of non-basal origin which makes them unique. It has
been observed that Indian breast cancer patients have a
higher tendency to have triple negative tumors as com-
pared to western patients. Incidence of triple negative
breast cancer in Indian breast cancer patients has been re-
ported between 19.9- to 24.8% compared to 15% in the
SEER, and there is significant correlation of TN Breastcancer with younger age (<35 years, P < 0.003) and high
level of p53 mutations (P < 0.001). The younger the age
of the patient, the greater are the chances of the cancer
being ER negative, with 63.5% of patients under 50 years
of age having ER negative tumors, and 33% of patients
under 50 years of age having TNBC [52]. Khokhar et al.,
[53] reported that Estrogen (ER) and progesterone re-
ceptors (PR) are found positive in only 20-45% of In-
dian patients. ER-positive rates were reported to be
lower in Indian patients than those in western coun-
tries. Rao et al., [54] reported that 33% of triple nega-
tive phenotype breast carcinomas show expression of
basal markers (CK5/6 and/or over-expression of EGFR)
and that “Triple negative” status cannot be used as a
surrogate for “basal marker expression”.
NIPBC-1 and NIPBC-2 both formed large colonies on
soft agar confirming the transformed nature of both the
two established cell lines since the ability to form an-
chorage independent colonies is related to transformed
nature of the cells [55]. Further, these cell lines showed
positivity for invasion on matrigel confirming their ma-
lignant nature.
Both NIPBC-1 and NIPBC-2 cell lines have shown an-
euploidy upon karyotyping, which is a feature of neo-
plastic cells, supporting their neoplastic origin. Further
they exhibited several translocations and rearrangements
pointing towards their neoplastic nature. The karyotypes
of both NIPBC-1 and NIPBC-2 cell lines exhibit isochro-
mosome 17q. The isochromosome 17, i (17q) is a rela-
tively common karyotype abnormality, that results in
loss of the short arm (17p) and duplication of the long
arm (17q) leading to a single copy of 17p and three cop-
ies of 17q, that has been observed in solid tumors such
as medulloblastoma, gastric cancer, bladder and breast
cancers, associated with tumor development and pro-
gression [56,57]. This is linked to poor survival outcome
due to the complex conditions of two important prog-
nostic determinants: loss of tumor suppressors (chromo-
some 17p) and high expression of oncogenes c-myc
(MYCC) or N-myc (MYCN) [58]. Chromosomal gains/
loses among the early and late passages were observed.
The karyotypes of the late passages of cell lines showed
less variability of numerical aberrations apparently due
to clonal adaptation to in vitro conditions. However we
would like to point out that cell lines are autonomous
dynamic systems with an unlimited lifespan in culture.
Numerous studies [59] have reported changes of cell line
Karyotype during prolonged cultivation due to changes
of culture conditions. It was also demonstrated that even
in characterized cell lines, because these cells are con-
tinually evolving, there is heterogeneity in karyotypes
within the same culture [60,61].
Mutations in tumor suppressor genes BRCA1/2 and
P53 genes are significant contributing factors for breast
(a) 
NIPBC1 NIPBC2




Figure 14 (See legend on next page.)
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Figure 14 Sequence variations found in BRCA1 and BRCA2 genes in NIPBC-1 and NIPBC-2. (a) BRCA1 exon 11 polymorphism, g. 2201 C > T
heterozygous allele (Gen Bank Id U14680.1) (b) BRCA1Exon 11- g.2731 C > T heterozygous allele (Gen Bank Id U14680.1) (c) BRCA1 exon11-g.3232
A > G heterozygous in both the cell lines (Gen Bank Id U14680.1) (d) BRCA1 Exon 11- g.3667 G > A heterozygous in in both cell lines (Gen
Bank Id U14680.1) (e) BRCA2 exon11- g. 3199 A > G heterozygous in both the cell lines (Gen Bank Id U14680.1).
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for mutations/ polymorphisms in these genes. Genetic
mutation or allelic polymorphisms in p53 gene are the
most common genetic changes associated with much
cancer susceptibility in human cancers, such as cervical
cancer, breast cancer, lung and colorectal cancer [62].
Although no mutation in coding regions of p53 gene has
been noticed in both NIPBC-1 and NIPBC-2 cell lines,
however a C/G polymorphism, g.417 C > G, at codon 72
has been found in NIPBC-2 cell line leading to arginine
(A72) being replaced by proline (P72). Numerous poly-
morphisms in the wild-type p53 have been reported in
both the coding and noncoding regions [63]. Of the five
polymorphisms described in the coding region, polymor-
phisms in codon 47 and 72 in exon 4 are functionally
well characterized. More common of the two, codon 72
polymorphism is a single-base substitution of cytosine
for guanine, leading to arginine (A72) being replaced by
proline (P72) [63], and this has been reported to be asso-
ciated with the risk of several cancers [64-68]. The distri-
bution of the three genotypes (Arg/Arg, Arg/Pro and
Pro/Pro) depends largely on the ethnic composition of
the studied population [69]. Even though, the p53Arg72
and p53Pro72 proteins do not differ in their ability to
bind to DNA, they bind to components of different tran-
scriptional machinery, influencing differential suscepti-
bility to cancer [70,71]. The p53Arg72 protein induces
apoptosis faster and suppresses transformation moreFigure 15 TP53 mutational analysis. NIPBC-2 cell line has heterozygous
P72R (Pro/Arg allele).efficiently than the p53Pro72 protein [62,72]. The p53
Arg72Arg polymorphism may be used as a stratification
marker in screening individuals at a high risk of breast
cancer [73,74].
Mutations in BRCA1 and BRCA2 genes are associated
with predisposition to breast cancer; hence we have
screened both the cell lines for mutations/ polymorphisms
in these genes. Several polymorphisms were observed,
among polymorphisms in BRCA1 exon 11, g.2201 C > T is
a frequent polymorphism reported in US [75,76], and
European population [75]; while polymorphism at nucleo-
tide g.3667 G > A had earlier been reported in north In-
dian population [22]. The other polymorphisms g2731
C > T, g.3232 A > G and g.3667 G > A in exon 11 of
BRCA1 have been reported in Korean population
[32,77]. The BRCA2 Exon14 g.7470 A > G polymorph-
ism found in both the cell lines had also been reported
earlier in north Indian population [32]. The exon
11 g.3199 A > G polymorphism in BRCA2 was reported
by WECARE Study Collaborative Group in US and
European patients and is also reported in Chinese
population [75,78].
CSCs have been isolated from many solid tumors, in-
cluding breast [36,79], pancreatic [80,81], brain [82,83],
colon [84-86], liver [87], head/neck [88], ovarian [89,90],
and melanoma [91,92]. CSCs were first isolated and
characterized by Al-Hajj et al. using the cell surface
marker CD44+/CD24−/low/Lin − and recapitulated theC/G, g.417 C > G (NM_000546.5), at codon72 of exon 4, resulting in p.
Figure 17 Representative pictures of mammospheres formed
by NIPBC1 & NIPBC-2 cell lines. (Magnification- 40x, inset
mag- 100x).
Unstained CD 44+/ 24-
0.2
MCF7
Unstained CD 44+/ 24-
0.1
NIPBC-2






Figure 16 Flow cytometry sorting of MCF7, NIPBC-1 and NIPBC-2 cells using CD44 and CD24 markers. Cells were analyzed by
fluorescence-activated cell sorting (FACS) using anti-CD44 and anti-CD24 antibodies.
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nude mice [36]. Both NIPBC-1 and NIPBC-2 cell lines
showed the presence of 0.2% and 0.1% of CD44+/CD24-
breast cancer stem cells respectively which is relatively
similar to the commercially available breast cancer cell
line. When plated in serum free, non-adherent conditions
as described earlier [33], both NIPBC-1 and NIPBC-2 cell
lines formed mammospheres (Figure 17) and could be fur-
ther passaged for three generations.
Molecular analysis of the cell lines was done to iden-
tify unique properties of the cell lines. Short tandem re-
peat (STR) profiling was done to ensure the integrity of
human cell lines. The STR profile of NIPBC-1 and 2
found to be unique and do not match among themselves
and also with other cell lines in the laboratory that are
being used, which shows these two cell lines are novel.
Although a number of normal and breast cancer cell
lines established from western patients are available,
there is a paucity of cell lines established from Indian
breast cancer patients. So far only two breast cancer cell
lines have been established from late onset breast cancer
patients (>60 years) using primary tumors [24], hence
the two cell lines we have established in the present
study are unique with respect to the ethnicity also as
these are the first breast cancer cell lines to be estab-
lished from Indian continent representing early onsetbreast cancers. In conclusion, in the present study we
have established two novel triple negative breast can-
cer cell lines, NIPBC-1 and NIPBC-2 from primary tu-
mors of two early onset breast cancers (<40 years),
which may serve as valuable in vitro models to study
breast tumorigenesis in young breast cancer patients
and identification of unique therapeutic targets.
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